Figure 1.
Mechanisms implicated in the beneficial effects of sodium-glucose co-transporter-2 inhibitors on type 2 diabetes mellitus-associated nonalcoholic fatty liver disease.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.